(Q37084127)

18 August 2017

1 reference

title

Current controversies in the treatment of testicular cancer (English)

1 reference

18 August 2017

Current controversies in the management of testicular cancer (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

3 December 2022

author name string

A. Horwich

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827326

3 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1827326

3 December 2022

publication date

1 January 1991

1 reference

full work available at URL

18 August 2017

https://api.elsevier.com/content/article/PII:027753799190539P?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

https://api.elsevier.com/content/article/PII:027753799190539P?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

European Journal of Cancer

3 December 2022

published in

1 reference

18 August 2017

27

1 reference

18 August 2017

3

1 reference

18 August 2017

322-326

1 reference

Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients

18 August 2017

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Cytogenetic studies of human testicular germ cell tumours

3 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Autoimmune phenomena and cytogenetic findings in a patient with carcinoma (seminoma) in situ

3 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis?

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Carcinoma in situ of the testis

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Residual carcinoma-in-situ of contralateral testis after chemotherapy

3 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Radiation treatment of carcinoma-in-situ of testis

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Questions in the management of seminoma

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Radiotherapy for stage I seminoma testis: results of treatment and complications

3 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

A study of post-orchiectomy surveillance in stage I testicular seminoma

3 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Orchidectomy alone for stage I seminoma of the testis

3 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Results of radiotherapy for stage II testicular seminoma

3 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Therapeutic guidelines and results in advanced seminoma

3 December 2022

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Cisplatin combination chemotherapy in advanced seminoma

3 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Simple nontoxic treatment of advanced metastatic seminoma with carboplatin

3 December 2022

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy

3 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience

3 December 2022

24

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer

3 December 2022

26

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone

3 December 2022

30

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy

3 December 2022

31

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SW

3 December 2022

32

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Germ cell tumour chemotherapy

3 December 2022

34

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies

3 December 2022

36

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Relation of proliferative activity to survival in patients with advanced germ cell cancer

3 December 2022

38

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy

3 December 2022

39

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

3 December 2022

41

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

3 December 2022

42

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors

3 December 2022

43

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis

3 December 2022

44

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients

3 December 2022

45

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

3 December 2022

47

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours

3 December 2022

49

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

3 December 2022

51

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90539-P

3 December 2022

Identifiers

1 reference

18 August 2017

1 reference